Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Harmony Biosciences's operating income for the twelve months ending Jun 30, 2026 was $230.65M, up 4.0% year over year. For fiscal 2025 it was $208.47M, up 9.2% from the year before. The highest annual figure on record is $208.47M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.47M | +9.2% |
| FY2024 | Dec 31, 2024 | $190.83M | -0.6% |
| FY2023 | Dec 31, 2023 | $192.03M | +59.8% |
| FY2022 | Dec 31, 2022 | $120.19M | +37.3% |
| FY2021 | Dec 31, 2021 | $87.53M | +415.3% |
| FY2020 | Dec 31, 2020 | $16.99M | – |
| FY2019 | Dec 31, 2019 | -$145.90M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $89.32M | +85.4% |
| Q1 FY2026 | Mar 31, 2026 | $37.29M | -33.7% |
| Q4 FY2025 | Dec 31, 2025 | $38.56M | -30.8% |
| Q3 FY2025 | Sep 30, 2025 | $65.49M | +6.1% |
| Q2 FY2025 | Jun 30, 2025 | $48.18M | +125.6% |
| Q1 FY2025 | Mar 31, 2025 | $56.25M | +8.1% |
| Q4 FY2024 | Dec 31, 2024 | $55.73M | +38.6% |
| Q3 FY2024 | Sep 30, 2024 | $61.71M | -4.3% |
| Q2 FY2024 | Jun 30, 2024 | $21.36M | -54.5% |
| Q1 FY2024 | Mar 31, 2024 | $52.03M | +28.7% |
| Q4 FY2023 | Dec 31, 2023 | $40.20M | -15.6% |
| Q3 FY2023 | Sep 30, 2023 | $64.51M | +442.0% |
| Q2 FY2023 | Jun 30, 2023 | $46.90M | +41.6% |
| Q1 FY2023 | Mar 31, 2023 | $40.42M | +46.7% |
| Q4 FY2022 | Dec 31, 2022 | $47.61M | +66.3% |
| Q3 FY2022 | Sep 30, 2022 | $11.90M | -43.5% |
| Q2 FY2022 | Jun 30, 2022 | $33.12M | +42.1% |
| Q1 FY2022 | Mar 31, 2022 | $27.56M | +89.6% |
| Q4 FY2021 | Dec 31, 2021 | $28.63M | +269.1% |
| Q3 FY2021 | Sep 30, 2021 | $21.05M | +102.8% |
| Q2 FY2021 | Jun 30, 2021 | $23.31M | +218.9% |
| Q1 FY2021 | Mar 31, 2021 | $14.53M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.76M | – |
| Q3 FY2020 | Sep 30, 2020 | $10.38M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$33.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.80M | – |
See a number that looks wrong?